# Emilia Mellado

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 105 papers | 8,769 citations | 34105<br>52 h-index | 42399<br>92 g-index |
| 110 all docs | 110 docs citations | 110 times ranked | 5736 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism. PLoS Medicine, 2008, 5, e219. | 8.4 | 630 |
| 2 | Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infectious Diseases, The, 2009, 9, 789-795. | 9.1 | 524 |
| 3 | A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations. Antimicrobial Agents and Chemotherapy, 2007, 51, 1897-1904. | 3.2 | 443 |
| 4 | Multiple-Triazoleâ€“Resistant Aspergillosis. New England Journal of Medicine, 2007, 356, 1481-1483. | 27.0 | 360 |
| 5 | Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi. Antimicrobial Agents and Chemotherapy, 2006, 50, 917-921. | 3.2 | 279 |
| 6 | Identification of Two Different 14-Î± Sterol Demethylase-Related Genes ( cyp51A and cyp51B ) in Aspergillus fumigatus and Other Aspergillus species. Journal of Clinical Microbiology, 2001, 39, 2431-2438. | 3.9 | 276 |
| 7 | <i>Aspergillus</i> Section <i>Fumigati</i> : Antifungal Susceptibility Patterns and Sequence-Based Identification. Antimicrobial Agents and Chemotherapy, 2008, 52, 1244-1251. | 3.2 | 233 |
| 8 | Environmental Study of Azole-Resistant <i>Aspergillus fumigatus</i> and Other Aspergilli in Austria, Denmark, and Spain. Antimicrobial Agents and Chemotherapy, 2010, 54, 4545-4549. | 3.2 | 217 |
| 9 | Substitutions at Methionine 220 in the 14Î±-Sterol Demethylase (Cyp51A) of Aspergillus fumigatus Are Responsible for Resistance In Vitro to Azole Antifungal Drugs. Antimicrobial Agents and Chemotherapy, 2004, 48, 2747-2750. | 3.2 | 200 |
| 10 | Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in <i>Aspergillus fumigatus</i>. Antimicrobial Agents and Chemotherapy, 2008, 52, 2468-2472. | 3.2 | 196 |
| 11 | Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. Journal of Antimicrobial Chemotherapy, 2008, 61, 805-809. | 3.0 | 191 |
| 12 | Susceptibility Patterns and Molecular Identification of Trichosporon Species. Antimicrobial Agents and Chemotherapy, 2005, 49, 4026-4034. | 3.2 | 173 |
| 13 | Aspergillus Species and Other Molds in Respiratory Samples from Patients with Cystic Fibrosis: a Laboratory-Based Study with Focus on Aspergillus fumigatus Azole Resistance. Journal of Clinical Microbiology, 2011, 49, 2243-2251. | 3.9 | 164 |
| 14 | The Aspergillus fumigatus chsC and chsG genes encode Class III chitin synthases with different functions. Molecular Microbiology, 1996, 20, 667-679. | 2.5 | 141 |
| 15 | Triazole Resistance in Aspergillus Species: An Emerging Problem. Drugs, 2017, 77, 599-613. | 10.9 | 140 |
| 16 | G484S Amino Acid Substitution in Lanosterol 14-Î± Demethylase ( ERG11 ) Is Related to Fluconazole Resistance in a Recurrent Cryptococcus neoformans Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2003, 47, 3653-3656. | 3.2 | 124 |
| 17 | A New Approach to Drug Discovery: High-Throughput Screening of Microbial Natural Extracts against Aspergillus fumigatus Using Resazurin. Journal of Biomolecular Screening, 2012, 17, 542-549. | 2.6 | 120 |
| 18 | Ergosterol biosynthesis in Aspergillus fumigatus: its relevance as an antifungal target and role in antifungal drug resistance. Frontiers in Microbiology, 2012, 3, 439. | 3.5 | 120 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids, 2008, 73, 339-347. | 1.8 | 115 |
| 20 | Aspergillus fumigatus chsE:A Gene Related toCHS3ofSaccharomyces cerevisiaeand Important for Hyphal Growth and Conidiophore Development but Not Pathogenicity. Fungal Genetics and Biology, 1997, 21, 141-152. | 2.1 | 114 |
| 21 | Comparative Evaluation of NCCLS M27-A and EUCAST Broth Microdilution Procedures for Antifungal Susceptibility Testing of Candida Species. Antimicrobial Agents and Chemotherapy, 2002, 46, 3644-3647. | 3.2 | 113 |
| 22 | Targeted Gene Disruption of the 14-Î± Sterol Demethylase ( cyp51A ) in Aspergillus fumigatus and Its Role in Azole Drug Susceptibility. Antimicrobial Agents and Chemotherapy, 2005, 49, 2536-2538. | 3.2 | 113 |
| 23 | Triazole Resistance in Aspergillus spp.: A Worldwide Problem?. Journal of Fungi (Basel, Switzerland), 2016, 2, 21. | 3.5 | 108 |
| 24 | Rapid Detection of Triazole Antifungal Resistance in <i>Aspergillus fumigatus</i>. Journal of Clinical Microbiology, 2008, 46, 1200-1206. | 3.9 | 101 |
| 25 | Inoculum Standardization for Antifungal Susceptibility Testing of Filamentous Fungi Pathogenic for Humans. Journal of Clinical Microbiology, 2001, 39, 1345-1347. | 3.9 | 99 |
| 26 | Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Medicine, 2004, 30, 724-728. | 8.2 | 99 |
| 27 | The non-mammalian host<i>Galleria mellonella</i>can be used to study the virulence of the fungal pathogen<i>Candida tropicalis</i>and the efficacy of antifungal drugs during infection by this pathogenic yeast. Medical Mycology, 2013, 51, 461-472. | 0.7 | 98 |
| 28 | Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. Journal of Antimicrobial Chemotherapy, 2005, 55, 312-316. | 3.0 | 93 |
| 29 | Current status of antifungal resistance and its impact on clinical practice. British Journal of Haematology, 2014, 166, 471-484. | 2.5 | 93 |
| 30 | Deciphering the role of the chitin synthase families 1 and 2 in the<i>in vivo</i>and<i>in vitro</i>growth of<i>A</i><i>spergillus fumigatus</i>by multiple gene targeting deletion. Cellular Microbiology, 2014, 16, 1784-1805. | 2.1 | 90 |
| 31 | Scopulariopsis brevicaulis , a Fungal Pathogen Resistant to Broad-Spectrum Antifungal Agents. Antimicrobial Agents and Chemotherapy, 2003, 47, 2339-2341. | 3.2 | 83 |
| 32 | Cell wall biogenesis in a double chitin synthase mutant (chsGâˆ'/chsEâˆ') of Aspergillus fumigatus. Fungal Genetics and Biology, 2003, 38, 98-109. | 2.1 | 82 |
| 33 | Members of protein Oâ€mannosyltransferase family in <i>Aspergillus fumigatus</i> differentially affect growth, morphogenesis and viability. Molecular Microbiology, 2010, 76, 1205-1221. | 2.5 | 81 |
| 34 | Genetic Relatedness versus Biological Compatibility between Aspergillus fumigatus and Related Species. Journal of Clinical Microbiology, 2014, 52, 3707-3721. | 3.9 | 79 |
| 35 | In Vitro Activities of Three Licensed Antifungal Agents against Spanish Clinical Isolates of Aspergillus spp. Antimicrobial Agents and Chemotherapy, 2003, 47, 3085-3088. | 3.2 | 78 |
| 36 | Galactosaminogalactan activates the inflammasome to provide host protection. Nature, 2020, 588, 688-692. | 27.8 | 78 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Proposal for a unified nomenclature for targetâ€site mutations associated with resistance to fungicides. Pest Management Science, 2016, 72, 1449-1459. | 3.4 | 76 |
| 38 | <i>Candida parapsilosis</i>,<i>Candida orthopsilosis</i>, and<i>Candida metapsilosis</i>virulence in the non-conventional host<i>Galleria mellonella</i>. Virulence, 2014, 5, 278-285. | 4.4 | 73 |
| 39 | Susceptibility Testing and Molecular Classification of <i>Paecilomyces</i> spp. Antimicrobial Agents and Chemotherapy, 2008, 52, 2926-2928. | 3.2 | 72 |
| 40 | In Vitro Activities of 35 Double Combinations of Antifungal Agents against <i>Scedosporium apiospermum</i> and <i>Scedosporium prolificans</i>. Antimicrobial Agents and Chemotherapy, 2008, 52, 1136-1139. | 3.2 | 72 |
| 41 | A multigene family related to chitin synthase genes of yeast in the opportunistic pathogen Aspergillus fumigatus. Molecular Genetics and Genomics, 1995, 246, 353-359. | 2.4 | 70 |
| 42 | Species Identification and Antifungal Susceptibility Patterns of Species Belonging to <i>Aspergillus</i> Section <i>Nigri</i>. Antimicrobial Agents and Chemotherapy, 2009, 53, 4514-4517. | 3.2 | 70 |
| 43 | Identification of Pathogenic Rare Yeast Species in Clinical Samples: Comparison between Phenotypical and Molecular Methods. Journal of Clinical Microbiology, 2010, 48, 1895-1899. | 3.9 | 70 |
| 44 | The ZrfC alkaline zinc transporter is required for<i>A</i><i>spergillus fumigatus</i>virulence and its growth in the presence of the Zn/Mn-chelating protein calprotectin. Cellular Microbiology, 2014, 16, 548-564. | 2.1 | 70 |
| 45 | Molecular epidemiology and antifungal susceptibility patterns of<i>Sporothrix schenckii</i>isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Medical Mycology, 2008, 46, 141-151. | 0.7 | 68 |
| 46 | Combined Activity In Vitro of Caspofungin, Amphotericin B, and Azole Agents against Itraconazole-Resistant Clinical Isolates of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2005, 49, 1232-1235. | 3.2 | 65 |
| 47 | In Vitro Activities of 10 Combinations of Antifungal Agents against the Multiresistant Pathogen Scopulariopsis brevicaulis. Antimicrobial Agents and Chemotherapy, 2006, 50, 2248-2250. | 3.2 | 65 |
| 48 | Functional analysis of the fungal/plant class chitinase family in Aspergillus fumigatus. Fungal Genetics and Biology, 2011, 48, 418-429. | 2.1 | 65 |
| 49 | Cloning and characterization ofchsD, a chitin synthase-like gene ofAspergillus fumigatus. FEMS Microbiology Letters, 1996, 143, 69-76. | 1.8 | 59 |
| 50 | Insight into the Significance of Aspergillus fumigatus cyp51A Polymorphisms. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 57 |
| 51 | Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida auris. Frontiers in Cellular and Infection Microbiology, 2019, 9, 83. | 3.9 | 57 |
| 52 | Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. Journal of Antimicrobial Chemotherapy, 2000, 46, 475-477. | 3.0 | 56 |
| 53 | Influence of Glucose Supplementation and Inoculum Size on Growth Kinetics and Antifungal Susceptibility Testing of Candida spp. Journal of Clinical Microbiology, 2001, 39, 525-532. | 3.9 | 56 |
| 54 | Genotyping and Antifungal Susceptibility Profile of Dipodascus capitatus Isolates Causing Disseminated Infection in Seven Hematological Patients of a Tertiary Hospital. Journal of Clinical Microbiology, 2004, 42, 1832-1836. | 3.9 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Hitting the Caspofungin Salvage Pathway of Human-Pathogenic Fungi with the Novel Lasso Peptide Humidimycin (MDN-0010). Antimicrobial Agents and Chemotherapy, 2015, 59, 5145-5153. | 3.2 | 54 |
| 56 | Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. Journal of Antimicrobial Chemotherapy, 2005, 56, 1144-1147. | 3.0 | 52 |
| 57 | In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. Journal of Antimicrobial Chemotherapy, 2004, 53, 1086-1089. | 3.0 | 51 |
| 58 | Genome-Wide Comparative Analysis of Aspergillus fumigatus Strains: The Reference Genome as a Matter of Concern. Genes, 2018, 9, 363. | 2.4 | 51 |
| 59 | Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 6975-6982. | 3.2 | 50 |
| 60 | In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Diagnostic Microbiology and Infectious Disease, 2003, 45, 199-202. | 1.8 | 49 |
| 61 | In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 3107-3111. | 3.2 | 49 |
| 62 | A novel family of dehydrin-like proteins is involved in stress response in the human fungal pathogen<i>Aspergillus fumigatus</i>. Molecular Biology of the Cell, 2011, 22, 1896-1906. | 2.1 | 48 |
| 63 | Resistance to Voriconazole Due to a G448S Substitution in Aspergillus fumigatus in a Patient with Cerebral Aspergillosis. Journal of Clinical Microbiology, 2012, 50, 2531-2534. | 3.9 | 48 |
| 64 | Standardization of Antifungal Susceptibility Variables for a Semiautomated Methodology. Journal of Clinical Microbiology, 2001, 39, 2513-2517. | 3.9 | 46 |
| 65 | In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi. Antimicrobial Agents and Chemotherapy, 2005, 49, 5136-5138. | 3.2 | 46 |
| 66 | Aspergillus fumigatus C-5 Sterol Desaturases Erg3A and Erg3B: Role in Sterol Biosynthesis and Antifungal Drug Susceptibility. Antimicrobial Agents and Chemotherapy, 2006, 50, 453-460. | 3.2 | 45 |
| 67 | Activity Profile In Vitro of Micafungin against Spanish Clinical Isolates of Common and Emerging Species of Yeasts and Molds. Antimicrobial Agents and Chemotherapy, 2009, 53, 2192-2195. | 3.2 | 45 |
| 68 | Invasive aspergillosis caused by cryptic Aspergillus species: a report of two consecutive episodes in a patient with leukaemia. Journal of Medical Microbiology, 2013, 62, 474-478. | 1.8 | 43 |
| 69 | Analysis of the Influence of Tween Concentration, Inoculum Size, Assay Medium, and Reading Time on Susceptibility Testing of Aspergillus spp. Journal of Clinical Microbiology, 2005, 43, 1251-1255. | 3.9 | 41 |
| 70 | Role of Aspergillus lentulus 14-Î± Sterol Demethylase (Cyp51A) in Azole Drug Susceptibility. Antimicrobial Agents and Chemotherapy, 2011, 55, 5459-5468. | 3.2 | 40 |
| 71 | First detection of Aspergillus fumigatus azole-resistant strain due to Cyp51A TR46/Y121F/T289A in an azole-naive patient in Spain. New Microbes and New Infections, 2015, 6, 33-34. | 1.6 | 40 |
| 72 | Molecular identification, antifungal resistance and virulence of <i>Cryptococcus neoformans</i> and <i>Cryptococcus deneoformans</i> isolated in Seville, Spain. Mycoses, 2017, 60, 40-50. | 4.0 | 40 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 73 | Current section and species complex concepts in <i>Aspergillus:</i> recommendations for routine daily practice. Annals of the New York Academy of Sciences, 2012, 1273, 18-24. | 3.8 | 39 |
| 74 | Genotype distribution of clinical isolates of Trichosporon asahii based on sequencing of intergenic spacer 1. Diagnostic Microbiology and Infectious Disease, 2007, 58, 435-440. | 1.8 | 36 |
| 75 | Two KTR Mannosyltransferases Are Responsible for the Biosynthesis of Cell Wall Mannans and Control Polarized Growth in <i>Aspergillus fumigatus</i>. MBio, 2019, 10, . | 4.1 | 31 |
| 76 | A New Aspergillus fumigatus Typing Method Based on Hypervariable Tandem Repeats Located within Exons of Surface Protein Coding Genes (TRESP). PLoS ONE, 2016, 11, e0163869. | 2.5 | 30 |
| 77 | Comparison of Two Highly Discriminatory Typing Methods to Analyze Aspergillus fumigatus Azole Resistance. Frontiers in Microbiology, 2018, 9, 1626. | 3.5 | 27 |
| 78 | Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in Aspergillus Species Received within a Surveillance Program on Antifungal Resistance in Spain. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 27 |
| 79 | A Cyp51B Mutation Contributes to Azole Resistance in Aspergillus fumigatus. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overl | 3.5 | 27 |
| 80 | Clinical relevance of resistance to antifungals. International Journal of Antimicrobial Agents, 2008, 32, S111-S113. | 2.5 | 22 |
| 81 | Three-dimensional models of 14Î±-sterol demethylase (Cyp51A) from Aspergillus lentulus and Aspergillus fumigatus: an insight into differences in voriconazole interaction. International Journal of Antimicrobial Agents, 2011, 38, 426-434. | 2.5 | 22 |
| 82 | Fitness Studies of Azole-Resistant Strains of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2015, 59, 7866-7869. | 3.2 | 22 |
| 83 | Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia. Revista Iberoamericana De Micologia, 2013, 30, 64-68. | 0.9 | 20 |
| 84 | Antifungal susceptibility profile of clinical Alternaria spp. identified by molecular methods. Journal of Antimicrobial Chemotherapy, 2011, 66, 2585-2587. | 3.0 | 17 |
| 85 | Aspergillus fumigatus Cross-Resistance between Clinical and Demethylase Inhibitor Azole Drugs. Applied and Environmental Microbiology, 2021, 87, . | 3.1 | 16 |
| 86 | COVID-19 Associated Pulmonary Aspergillosis (CAPA): Hospital or Home Environment as a Source of Life-Threatening Aspergillus fumigatus Infection?. Journal of Fungi (Basel, Switzerland), 2022, 8, 316. | 3.5 | 15 |
| 87 | Detection of Resistance to Amphotericin B in Candida Isolates by Using Iso-Sensitest Broth. Antimicrobial Agents and Chemotherapy, 2001, 45, 2070-2074. | 3.2 | 14 |
| 88 | Time of Incubation for Antifungal Susceptibility Testing of <i>Aspergillus fumigatus</i> : Can MIC Values Be Obtained at 24 Hours?. Antimicrobial Agents and Chemotherapy, 2007, 51, 4502-4504. | 3.2 | 13 |
| 89 | Polyphasic characterization of fungal isolates from a published case of invasive aspergillosis reveals misidentification of Aspergillus felis as Aspergillus viridinutans. Journal of Medical Microbiology, 2014, 63, 617-619. | 1.8 | 13 |
| 90 | Point Mutations in the 14-Î± Sterol Demethylase Cyp51A or Cyp51C Could Contribute to Azole Resistance in Aspergillus flavus. Genes, 2020, 11, 1217. | 2.4 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Multiresistance to Nonazole Fungicides in Aspergillus fumigatus TR <sub>34</sub> /L98H Azole-Resistant Isolates. Antimicrobial Agents and Chemotherapy, 2021, 65, e0064221. | 3.2 | 13 |
| 92 | Ribosomic DNA intergenic spacer 1 region is useful when identifying Candida parapsilosis spp. complex based on high-resolution melting analysis. Medical Mycology, 2014, 52, 472-481. | 0.7 | 12 |
| 93 | New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. European Journal of Medicinal Chemistry, 2016, 116, 281-289. | 5.5 | 10 |
| 94 | Hospital Environment as a Source of Azole-Resistant Aspergillus fumigatus Strains with TR34/L98H and G448S Cyp51A Mutations. Journal of Fungi (Basel, Switzerland), 2021, 7, 22. | 3.5 | 10 |
| 95 | Antifungal drug resistance in molds: Clinical and microbiological factors. Current Fungal Infection Reports, 2008, 2, 36-42. | 2.6 | 9 |
| 96 | Azasordarins: Susceptibility of Fluconazole-Susceptible and Fluconazole-Resistant Clinical Isolates of Candida spp. to GW 471558. Antimicrobial Agents and Chemotherapy, 2001, 45, 1905-1907. | 3.2 | 8 |
| 97 | Are Point Mutations in HMG-CoA Reductases (Hmg1 and Hmg2) a Step towards Azole Resistance in Aspergillus fumigatus?. Molecules, 2021, 26, 5975. | 3.8 | 5 |
| 98 | Could the determination of <i>Aspergillus fumigatus</i> mating type have prognostic value in invasive aspergillosis?. Mycoses, 2018, 61, 172-178. | 4.0 | 4 |
| 99 | Azole Antifungal Drugs: Mode of Action and Resistance. , 2021, , 427-437. | | 4 |
| 100 | Genetic Similarity among One Aspergillus flavus Strain Isolated from a Patient Who Underwent Heart Surgery and Two Environmental Strains Obtained from the Operating Room. Journal of Clinical Microbiology, 2000, 38, 2419-2422. | 3.9 | 4 |
| 101 | Galactomannan enzyme immunoassay and quantitative Real Time PCR as tools to evaluate the exposure and response in a rat model of aspergillosis after posaconazole prophylaxis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 571-576. | 0.5 | 2 |
| 102 | Antifungal Mechanisms of Action and Resistance. , 0, , 457-466. | | 1 |
| 103 | Presente y futuro de la micologÃa mÃ©dica. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2003, 21, 75-80. | 0.5 | 0 |
| 104 | Aspergillus as a Human Pathogen: an Evolutionary Perspective. , 0, , 591-601. | | 0 |
| 105 | An expanded agarâ€based screening method for azoleâ€resistant Aspergillus fumigatus. Mycoses, 2021, , . | 4.0 | 0 |